Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Alvocidib Plus Cytarabine/Mitoxantrone or Cytarabine/Daunorubicin in AML
jRCT2080223907Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of alvocidib in acute myeloid leukemia (AML) (2 arms), sponsored by Sumitomo Pharma. Primary endpoints: Safety and tolerability of ACM regimen and Safety and tolerability of A+7+3 regimen. Started May 2018; status: completed.
02
Drugs
alvocidib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080223907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223907.